drugset / Trial / NCT00712530

Single DermaVir Immunization in HIV-1 Infected Patients on HAART

NCT00712530 ↗

Phase 1 Completed 9 enrolled Genetic Immunity
Non-randomizedSingle-groupOpen-labelTreatment

Summary

* DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered topically with DermaPrep to target Langerhans cells. Langerhans cells with DermaVir migrate to lymph nodes and express HIV-like particles that induce immune responses to kill HIV-infected cells. * Hypothesis: Single DermaVir immunization is safe and immunogenic measured by induction of HIV-specific precursor/memory T cell responses. * GIHU004 was a phase I dose escalation study conducted in Hungary. It evaluated the safety and immunogenicity of three dosing regimens of topical DermaVir immunization for the treatment of HIV-infected individuals on fully suppressive highly active antiretroviral therapy (HAART).

Timeline

Start
2005-01
Primary completion
2006-06
Completion
2006-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DermaVir Vaccine 0.1 mg Topical
Subject DermaVir Vaccine 0.4 mg Topical
Subject DermaVir Vaccine 0.8 mg Topical